- Use of oral ribavirin leads to substantial cost avoidance with comparable clinical efficacy to aerosol administration for transplant recipients.
Why this matters
- Respiratory syncytial virus (RSV) infection can lead to significant morbidity and mortality for immunocompromised transplant patients.
- Aerosol ribavirin is FDA approved for treatment of RSV infection; however, there are administration barriers and increased cost associated with its use.
- Single-center, retrospective quality improvement study.
- Records for pediatric and adult solid organ or stem cell transplant patients who were prescribed ribavirin were reviewed.
- An economic analysis was performed based on drug acquisition cost.
- There were no observed poor clinical outcomes or adverse events in oral ribavirin patients.
- Substantial cost difference per dose for oral and aerosol: $1.42 vs $12,255.
- Cost avoidance per 206 patient-days: $2,522,915.
- Statistical analysis not performed for clinical outcomes.
- Single-center retrospective study.
- Presented at a conference without peer review.